Pediatric Glioblastoma Multiforme (GBM) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Pediatric Glioblastoma Multiforme (GBM) Market Outlook
Thelansis’s “Pediatric Glioblastoma
Multiforme (GBM) Market Outlook, Epidemiology, Competitive Landscape, and
Market Forecast Report – 2024 To 2034" covers disease overview,
epidemiology, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential Pediatric
Glioblastoma Multiforme (GBM) treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Pediatric Glioblastoma Multiforme
(GBM) Overview
Glioblastoma
multiforme (GBM) is a formidable disease, comprising 17% of adult intracranial
neoplasms. No identified risk factors are associated with GBM, except for
exposure to ionizing radiation. GBM is one of the most aggressive forms of
cancer in humans. Despite advancements in surgical techniques and additional
treatments, the average survival time remains approximately 1 year. In adults,
GBM is the most prevalent type of astrocytoma and is typically associated with
a grim prognosis, with a median survival of about 12 months. However, it is
rare in children. Around 65% of GBM cases primarily manifest in the cerebral
hemispheres, which govern higher cognitive functions such as speech, movement,
thought, and sensation. GBMs can also arise in other regions of the brain that
regulate sensory perception, temperature sensitivity, balance, and motor
function. The most prevalent symptoms of GBM include morning headaches,
lethargy, and seizures that vary depending on the type and location of the
tumor. Compression of neighboring brain structures due to the tumor’s position
can result in motor dysfunction, hormonal irregularities, or changes in
behavior and cognitive processes. GBMs are typically diagnosed between the ages
of 5 and 9, affecting both boys and girls equally. However, they occur more
frequently in children with specific genetic syndromes, including
neurofibromatosis 1, Li-Fraumeni syndrome, hereditary nonpolyposis colon
cancer, and tuberous sclerosis. The majority of GBM cases, however, have an unknown
cause. Treatment options for GBM may encompass neurosurgery, radiation therapy,
and chemotherapy.
Geography coverage:
G8 (United States, EU5 [France,
Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust
research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal
articles, third-party research databases)
Deliverables format and
updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated
dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant
support
*As per Thelansis’s policy, we
ensure that we include all the recent updates before releasing the report
content and market model.
Salient features of Market
Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated
through the top-down sales methodology
- Covers clinically and commercially-relevant patient
populations/ line of therapies
- Annualized drug-level sales and patient share
projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management
strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of
incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and
patient share?
- Which events will have the greatest impact on the
market’s trajectory?
- What insights do interviewed experts provide on
current and emerging treatments?
- Which pipeline products show the most promise, and
what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for
target profiles?
- What key regulatory and payer requirements must be
met to secure drug approval and favorable market access?
- and more…
Comments
Post a Comment